<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019067</url>
  </required_header>
  <id_info>
    <org_study_id>MCE-melena-2019</org_study_id>
    <nct_id>NCT04019067</nct_id>
  </id_info>
  <brief_title>Magnetically Controlled Capsule Endoscopy First vs. Standard Algorithm in Patients With Melena</brief_title>
  <acronym>FIRM</acronym>
  <official_title>Magnetically Controlled Capsule Endoscopy First vs. Standard Algorithm in Patients With Melena (FIRM Trial): a Multicenter, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MCE first algorithm is not inferior to standard of care algorithm in terms of further&#xD;
      bleeding in hemodynamically stable patients with acute overt and non-hematochezia GI&#xD;
      bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    few patients met all the inclusion criteria&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of bleeding lesions detection.</measure>
    <time_frame>1 month</time_frame>
    <description>Detection rate of bleeding lesions is defined as proportion of patients in whom a potential bleeding lesion is identified. Visualization of gross blood (fresh/coffee grounds) without any lesion will not be considered as a positive diagnosis. The panel will provide a diagnosis based upon the lesion presenting the highest potential for bleeding if there are many lesions detected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time of the bleeding lesions detected from admission</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of procedures patients underwent for detection of the bleeding lesions</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of colonoscopy needed</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of therapeutic intervention required of all patients</measure>
    <time_frame>1 month</time_frame>
    <description>Therapeutic interventions include therapeutic endoscopy, radiologic intervention or surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The length of hospital stay</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative direct cost of hospitalization</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to therapeutic intervention from presentation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of recurrent bleeding within 30 days of discharge</measure>
    <time_frame>1 month</time_frame>
    <description>Further bleeding is defined as overt (hematemesis, melena or hematochezia) or occult (anemia or fecal occult blood positive) bleeding requiring subsequent hospitalization or transfusion, and/or signs of hypovolemic shock (systolic blood pressure of &lt;100 mmHg and pulse rate &gt;100 per min) or a drop-in hemoglobin level of &gt;2g/dL per 24hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The all-cause mortality within 30 days of discharge</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Melena</condition>
  <arm_group>
    <arm_group_label>MCE first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the &quot;MCE first group&quot; will have a MCE deployed as the first detection method.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For patients randomized to the Standard Care Group, gastroenterologists choose which procedures to perform and when to perform them based on their interpretation of the patient's presentation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MCE first</intervention_name>
    <description>Patients randomized to the &quot;MCE first group&quot; will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours.</description>
    <arm_group_label>MCE first group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Presenting to the outpatient department or emergency department with melena (without&#xD;
             hematemesis) within the previous 48 hours&#xD;
&#xD;
          -  Hemodynamically stable (blood pressure &gt; 100/60 mmHg and heart rate &lt; 100 bpm) at&#xD;
             presentation&#xD;
&#xD;
          -  No endoscopy performed after the new onset of melena&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presenting with hematochezia and/or hematemesis within the previous 48 hours of&#xD;
             presentation&#xD;
&#xD;
          -  Hemodynamically stable after initial volume resuscitation&#xD;
&#xD;
          -  Drop of hemoglobin level ≥ 2 g/dL/day, and/or need of transfusion ≥ 2 units of packed&#xD;
             red blood cells per day&#xD;
&#xD;
          -  Contraindications of CE (e.g. dysphagia, Zenker's diverticulum, esophageal stricture,&#xD;
             known or suspected gastric or small bowel obstruction or perforation, gastroparesis,&#xD;
             history of upper gastrointestinal surgery or abdominal surgery altering&#xD;
             gastrointestinal anatomy, or post-abdominal radiation, etc.)&#xD;
&#xD;
          -  Presence of internal cardiac defibrillator (ICD), pacemaker and/or other implanted&#xD;
             electronic devices (cochlea, drug infusion pump, nerve stimulator, etc.) or magnetic&#xD;
             metal foreign bodies; possibility of requiring an MRI examination prior to capsule&#xD;
             excretion&#xD;
&#xD;
          -  Patients who cannot undergo surgery in the event of capsule retention&#xD;
&#xD;
          -  Pregnant and/or lactating women&#xD;
&#xD;
          -  Patients with altered mental status (such as hepatic encephalopathy)&#xD;
&#xD;
          -  Patients moribund from terminal malignant diseases or other end-stage illnesses with a&#xD;
             limited life expectancy&#xD;
&#xD;
          -  Unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhuan Liao</investigator_full_name>
    <investigator_title>M.D., Associate Professor, Associate Chief Physician</investigator_title>
  </responsible_party>
  <keyword>magnetically controlled capsule endoscopy</keyword>
  <keyword>detection algorithm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melena</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

